GlassScriptPhysician profile
Nicholas Robert Chuck
NPI 1891340410
$3,204.64
in general payments reported to CMS, 2019-2025
24 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $125 · 2023: $1,171 · 2024: $1,045 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.28 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.95 | 2023-2025 | |
| Novo Nordisk INC | $511.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $293.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Shield Therapeutics INC | $256.96 | 2023-2025 | Accrufer |
| Amgen INC. | $254.79 | 2023-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $217.85 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $148.97 | 2023-2024 | |
| Abbott Laboratories | $130.10 | 2022-2024 | Freestyle Libre 3 |
| Pfizer INC. | $128.22 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.57 | 2021-2025 | Jardiance |
| Dexcom, INC. | $94.49 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $84.73 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $75.30 | 2023-2025 | Airsupra, Fasenra |
| Biohaven Pharmaceuticals, INC. | $60.59 | 2021 | |
| Insulet Corporation | $34.82 | 2021-2024 | Omnipod |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.76 | 2022 | |
| Enterra Medical, INC. | $22.88 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.09 | 2024 | Gvoke Hypopen |
| Lifescan, INC. | $21.70 | 2023 | |
| Phadia US INC. | $19.73 | 2024 | Immunocap |
| Astellas Pharma US INC | $18.84 | 2024 | Veozah |
| Philips North America LLC | $17.80 | 2024 | (Ck6) Holter |
| Abiomed | $17.39 | 2024 | Impella |
| Mylan Specialty L.P. | $13.75 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Chuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.